In Q3, Aurobindo Pharma reported 19% YoY decline in net profit and missed consensus expectations due to 51% surge in R&D cost, which is expected to remain at elevated level over the next 6–7 quarters.
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
Unlock all research summaries
Follow top, independent analysts
Receive personalised alerts and emails
Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.